ABBV vs CRL
By Alex · Tickerpine
AbbVie Inc. vs Charles River Laboratories International, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | CRL |
|---|---|---|
| Price | $265.79 | $297.64 |
| Market cap | $469.68B | $14.34B |
| P/E ratio | 74.7 | — |
| ROE | — | -7.52% |
| Profit margin | 9.80% | -5.96% |
| Revenue growth | 10.20% | -2.70% |
| Dividend yield | 2.62% | — |
| Beta | 0.28 | 1.38 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs CRL in plain English
- ABBV is the bigger company — about 32.8× the market cap of CRL.
- ABBV is growing revenue faster (10% vs -3%).
- ABBV pays a dividend (2.62%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
CRL return calculator
See what $1,000 in Charles River Laboratories International, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.